Acquired Therapy Resistance

Acquired Therapy Resistance is the stable, typically genetically or epigenetically fixed loss of tumor sensitivity to a therapeutic agent that develops after a period of initial response, resulting from irreversible alterations selected for or induced during treatment. It represents the endpoint of resistance evolution, in which transient adaptive states consolidate into durable changes that persist even in the absence of continued drug exposure.

Defining Features

Stability Distinguishing It From Adaptive States

While therapy induced cell state adaptation and adaptive resistance can involve reversible, non-genetic tolerance, acquired resistance is characterized by heritable changes, most commonly somatic mutations, gene amplifications, or stable epigenetic marks, that persist through cell division independent of ongoing drug pressure.

Temporal Signature

Acquired resistance is clinically defined by disease progression following a documented period of response or stable disease on therapy, distinguishing it from intrinsic resistance, which is present from treatment onset, and marking the point at which the tumor cell population has been definitively remodeled by treatment.

Mechanistic Categories

Target Alteration

Mutations in the drug-binding site of the therapeutic target, or amplification and overexpression of the target itself, can restore pathway function or reduce drug binding affinity, directly negating the mechanism of action of the original therapy.

Pathway Bypass Through Genetic Alteration

Acquisition of mutations or amplifications in downstream effectors or parallel signaling components allows the tumor cell to sustain proliferative and survival signaling despite continued inhibition of the original target.

Drug Metabolism and Efflux Changes

Upregulation of drug efflux transporters or alterations in drug-metabolizing enzyme expression, once established as stable genetic or epigenetic changes, reduce effective intracellular drug concentration in a durable manner.

Histological and Lineage Transformation

In some tumor types, acquired resistance manifests as transformation to a histologically distinct phenotype, such as small cell transformation in epithelial tumors, representing a fixed identity change that confers independence from the original therapeutic vulnerability.

Clinical Detection and Characterization

Progression After Response

Radiographic or biomarker progression occurring after an initial documented response defines the clinical onset of acquired resistance, prompting repeat tumor sampling or liquid biopsy to characterize the underlying mechanism.

Resistance Mechanism Profiling

Molecular profiling of progressing tumor tissue or circulating tumor DNA at the time of acquired resistance identifies the specific genetic alteration responsible, guiding selection of next-line therapies targeting the newly acquired vulnerability.

Heterogeneity of Resistance Mechanisms

Multiple distinct acquired resistance mechanisms can emerge simultaneously in different regions of the same tumor or in different metastatic sites, reflecting parallel evolution under shared selective pressure and complicating uniform second-line treatment.

Therapeutic Response Strategies

Sequential Targeted Therapy

When the acquired resistance mechanism is identified, subsequent therapies can be selected to directly target the new resistance-conferring alteration, exemplified by later-generation inhibitors designed to overcome specific resistance mutations.

Combination Strategies to Preempt Acquisition

Upfront combination therapy targeting multiple pathway nodes simultaneously reduces the probability that a single acquired alteration can restore tumor fitness, thereby delaying the emergence of acquired resistance.

Quantitative Framing

This interval, measured across patient cohorts, characterizes the durability of response to a given therapy and provides a comparative metric for evaluating strategies designed to delay the onset of acquired resistance.